NOURIANZ市場：市場規模、予測、市場洞察-2032年

NOURIANZは、キサンチン誘導体構造を有するイストラデフィリンを含有しています。化学名は（E）-8-（3, 4-ジメトキシスチリル）-1, 3-ジエチル-7-メチル-3, 7ジヒドロ-1H-プリン-2, 6-ジオンで、分子式はC20H24N4O4です。

推奨用量は1日1回20mg経口投与であり、最大1日1回40mgまで増量可能です。食事の有無にかかわらず服用できます。肝障害のある患者中等度の肝障害を有する患者における推奨最大用量は1日1回20mgであり、重度の肝障害を有する患者におけるNOURIANZの使用は避けるべきです。また、1日20本以上（またはそれに相当する他のたばこ製品）の喫煙がある患者には、1日1回40mgの投与が推奨されます。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のNOURIANZ市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるNOURIANZの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 NOURIANZ市場評価

• パーキンソン病におけるNOURIANZ市場の見通し
• 米国と日本の分析
  • 米国と日本におけるパーキンソン病治療薬NOURIANZの市場規模
• 国別市場分析
  • 米国
  • 日本

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: NOURIANZ, Clinical Trial Description, 2023
• Table 2: NOURIANZ, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: NOURIANZ Market Size in the US and Japan, in USD million (2019-2032)
• Table 6: NOURIANZ Market Size in the US, in USD million (2019-2032)
• Table 7: NOURIANZ Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: NOURIANZ Market Size in the US and Japan, USD million (2019-2032)
• Figure 2: NOURIANZ Market Size in the United States, USD million (2019-2032)
• Figure 3: NOURIANZ Market Size in Japan, USD million (2019-2032)

"NOURIANZ Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about NOURIANZ for Parkinson's disease in the US and Japan. A detailed picture of the NOURIANZ for Parkinson's disease in the United States and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NOURIANZ for Parkinson's disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NOURIANZ market forecast analysis for Parkinson's disease in the US and Japan, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

NOURIANZ contains istradefylline, which has a xanthine derivative structure. The chemical name is (E)-8-(3, 4-dimethoxystyryl)-1, 3-diethyl-7-methyl-3, 7¬dihydro-1H-purine-2, 6-dione. Its molecular formula is C20H24N4O4.

Indication

NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing "off" episodes.

Dosage and administration

• The recommended dosage is 20 mg orally once daily, and the dosage may be increased to a maximum of 40 mg once daily.
• It may be taken with or without food.
• In patients with hepatic impairment: The maximum recommended dosage with moderate hepatic impairment is 20 mg once daily and the use of NOURIANZ in patients with severe hepatic impairment should be avoided.
• For patients who smoke 20 or more cigarettes per day (or the equivalent of another tobacco product), the recommended dosage is 40 mg once daily.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the NOURIANZ description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on NOURIANZ regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NOURIANZ research and development activities in Parkinson's disease across the United States and Japan.
• The report also covers the patents information with expiry timeline around NOURIANZ.
• The report contains forecasted sales of NOURIANZ for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for NOURIANZ in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NOURIANZ Analytical Perspective by DelveInsight

• In-depth NOURIANZ Market Assessment

This report provides a detailed market assessment of NOURIANZ for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• NOURIANZ Clinical Assessment

The report provides the clinical trials information of NOURIANZ for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NOURIANZ dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to NOURIANZ and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NOURIANZ in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of NOURIANZ from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NOURIANZ in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of NOURIANZ?
• What is the clinical trial status of the study related to NOURIANZ in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NOURIANZ development?
• What are the key designations that have been granted to NOURIANZ for Parkinson's disease?
• What is the forecasted market scenario of NOURIANZ for Parkinson's disease?
• What are the forecasted sales of NOURIANZ in the United States and Japan?
• What are the other emerging products available and how are these giving competition to NOURIANZ for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. NOURIANZ Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. NOURIANZ Market Assessment

• 5.1. Market Outlook of NOURIANZ in Parkinson's disease
• 5.2. The US and Japan Analysis
  • 5.2.1. Market Size of NOURIANZ in the US and Japan for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of NOURIANZ in the United States for Parkinson's disease
  • 5.3.2. Market Size of NOURIANZ in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options